NCT06585540 - A Pilot Study to Evaluate Barhemsys for the Prevention of Postoperative Nausea and Vomiting in the Bariatric Surgery Population | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

September 13, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

January 31, 2026

Conditions

Post Operative Nausea and Vomiting

Interventions

DRUG

Amisulpride IV Prevention

Patients in this arm will receive Amisulpride 5mg IV as a preventative dose after the induction of anesthesia

DRUG

Amisulpride IV Treatment

Patients in this arm will receive Amisulpride 10mg IV for first-line treatment of Post-Operative Nausea and Vomiting in the post-anesthesia care unit.

DRUG

Placebo Preventative

Patients in this arm will receive placebo (Normal Saline) while under general anesthesia

DRUG

Placebo Treatment

Patients in this Arm will receive placebo as first line treatment of Post-Operative Nausea and Vomiting in the Post Anesthesia Care Unit

Trial Locations (1)

98101

RECRUITING

Virginia Mason Medical Center, Seattle